Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value

$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck proQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%) (%)

Form 8-K Table 3a / 3b Product Sales

Quarterly Annual

Latest, Q2 2026

-9.0%

Period ended Jun 30, 2026

Change on a year earlier

-7.0 pts

-2.0% in Q2 2025

History

8 quarters

Since Q1 2024

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%) (%)	Year on year	Source
Q2 2026	Jun 30, 2026	-9.0%	-7.0 pts	Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025	Dec 31, 2025	2.0%	-2.0 pts	Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025	Sep 30, 2025	-3.0%	-4.0 pts	Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025	Jun 30, 2025	-2.0%	–	Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025	Mar 31, 2025	-3.0%	-7.0 pts	Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024	Dec 31, 2024	4.0%	–	Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024	Sep 30, 2024	1.0%	–	Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2024	Mar 31, 2024	4.0%	–	Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗

Cite this data

StockData. (2026). Merck ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%) (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_proquad_mmr_varivax_us_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.